drugset / Trial / NCT07668960

Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

NCT07668960 ↗

Phase 1/2 Not yet recruiting 60 enrolled Shanghai Mianyi Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The goal of this study is to learn about the safety, tolerability, immunogenicity and preliminary efficacy of BBM-C101 injection in patients with High-Grade Squamous Intraepithelial Lesion of the cervix. This study include two phases: Phase I and Phase IIa .

Timeline

Start
2026-06-17
Primary completion
2029-12-30
Completion
2029-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BBM-C101 Unknown — Subcutaneous